Novartis delivered high single-digit sales growth in 2025
Swiss pharma giant Novartis (NOVN: VX) today posted financial results, showing that fourth-quarter 2025 net sales were $13.3 billion (+1%, -1% constant currency - cc), with volume contributing 18 percentage points to growth. Generic competition had a negative impact of 15 percentage points, the company noted.
Net income for the quarter was $2.4 billion (-15%, -14% cc), impacted by higher income taxes. Earnings per share (EPS) were $1.26 (-11%, -11% cc), benefiting from the lower weighted average number of shares outstanding.
Non-generally-accepted accounting principles (GAAP) EPS of $2.03, surpassing expectations by $0.03. However, its revenue of $13.34 billion, which grew 1.4% year-over-year, fell short by $740 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze